| Literature DB >> 35524334 |
Matthew Holt1,2, Caitlin L Swalwell1,3, Gayle H Silveira4, Vivienne Tippett3, Tom P Walsh5,6, Simon R Platt1,2.
Abstract
INTRODUCTION: Patients with chronic foot/ankle pain are often referred for orthopaedic assessment. Psychological vulnerabilities influence pain states (including foot and ankle), therefore this study aimed to establish the prevalence and relative importance of compromised psychological health to perceived foot/ankle pain severity in people referred to an orthopaedic foot and ankle clinic with non-urgent presentations.Entities:
Keywords: Ankle; Body mass index; Depression; Foot; Mental health; Musculoskeletal pain
Mesh:
Year: 2022 PMID: 35524334 PMCID: PMC9074220 DOI: 10.1186/s13047-022-00536-5
Source DB: PubMed Journal: J Foot Ankle Res ISSN: 1757-1146 Impact factor: 3.050
Participant characteristics (n = 172)
| Characteristic | Median (Q1, Q3)a |
|---|---|
| Age, yrs | 60.9 (53.4, 71.7) |
| Sex, | 110 (64.0) |
| Weight, kg | 79.0 (68.0, 93.0) |
| Height, m | 168.0 (160.0, 176.0) |
| BMI, kg/m2 | 27.6 (24.4, 31.7) |
| Socio-economic disadvantage (IRSD) | 7.0 (6.0, 7.0) |
| Health-related quality of life (EQ-VAS) | 70.0 (50.0, 80.0) |
| Analgesia, | |
| Paracetamol | 85 (50.3) |
| Oral NSAIDs | 62 (36.9) |
| Codeine / other opioids | 40 (23.7) |
| Any analgesia, | 126 (74.1) |
| Smoking status, | |
| Current smoker | 10 (5.8) |
| Ex-smoker | 56 (32.6) |
| Non-smoker | 104 (60.5) |
| Presence of one of more comorbidity (SACQ), | 133 (78.2) |
aUnless otherwise indicated
Data missing from participants (n); height (4), weight (4), IRSD (1), EQ-VAS (3), paracetamol (3), NSAIDs (4), opioids (3), any analgesia (2), smoking status (2)
Abbreviations: BMI body mass index, EQ-VAS EuroQoL visual analogue scale, IRSD index of relative socio-economic disadvantage, NSAIDs non-steroidal anti-inflammatory drugs, SACQ self-administered comorbidity questionnaire, Q1 = lower quartile, Q3 = upper quartile
Most frequently reported comorbidities based on the SACQ (n = 172)
| Comorbidity | |
|---|---|
| Heart disease | 11 (6.5) |
| Hypertension | 56 (33.1) |
| Lung disease | 10 (5.9) |
| Diabetes | 16 (9.4) |
| Anaemia or other blood disease | 13 (7.7) |
| Kidney disease | 3 (1.8) |
| Liver disease | 2 (1.2) |
| Depression | 29 (17.2) |
| Cancer | 7 (4.1) |
| Stroke | 7 (4.2) |
| Osteoarthritis | 81 (47.9) |
| Back pain | 95 (56.5) |
| Rheumatoid arthritis | 27 (16.8) |
| Other | 33 (19.4) |
Values are n and percentage of valid responses. Data missing from participants (n); heart disease (4), hypertension (3), lung disease (2), diabetes (2), anaemia or other blood disease (3), kidney disease (2), liver disease (2), depression (3), cancer (2), stroke (4), osteoarthritis (3), back pain (4), rheumatoid arthritis (11), other (2)
Abbreviation: SACQ Self-Administered Comorbidity Questionnaire
Health-related quality of life dimensions, as measured by the EuroQoL-5D-5L (n = 172)
| Dimension | Level | ||||
|---|---|---|---|---|---|
| No problems | Slight problems | Moderate problems | Severe problems | Extreme problems | |
| Mobility | 19 (11.2) | 36 (21.2) | 76 (44.7) | 37 (21.8) | 2 (1.2) |
| Self-care | 110 (65.5) | 35 (20.8) | 17 (10.1) | 4 (2.4) | 1 (0.6) |
| Usual activity | 26 (15.5) | 43 (25.6) | 64 (38.0) | 28 (16.7) | 6 (3.6) |
| Pain / discomfort | 2 (1.2) | 26 (15.2) | 73 (42.7) | 60 (35.1) | 10 (5.8) |
| Anxiety / depression | 72 (42.6) | 49 (29.0) | 33 (19.5) | 7 (4.1) | 7 (4.1) |
Values are n (%)
Data missing from participants (n); mobility (2), self-care (4), usual activities (4), pain / discomfort (1), anxiety / depression (3)
Abbreviation: 5D-5L 5-Dimensions-5-Levels
Pain- and psychological health-related measures
| Pain Measures | Median (Q1, Q3)a |
|---|---|
| MOXFQa | |
| Walking / standing | 67.9 (50.0, 85.7) |
| Pain | 70.0 (55.0, 80.0) |
| Social interaction | 62.5 (37.5, 75.0) |
| MOXFQ-index | 65.6 (51.6, 79.7) |
| Depressive symptoms, | 83 (48.3) |
| Central sensitisation syndrome, | 66 (38.4) |
| PCS | |
| Rumination | 6.0 (2.0, 11.0) |
| Magnification | 3.5 (1.0, 6.25) |
| Helplessness | 9.0 (4.0, 15.0) |
| Pain catastrophisation, | 42 (24.4) |
aUnless otherwise indicated. aIn cases of bilateral foot pain, data reported for more painful foot
Data missing from participants (n); MOXFQ-index (5), depressive symptoms (8), central sensitisation syndrome (6), pain catastrophisation (26)
Abbreviations: MOXFQ Manchester-Oxford Foot and Ankle Questionnaire, PCS Pain Catastrophizing Scale, Q1 = lower quartile, Q3 = upper quartile
Hierarchical multiple linear regression investigating factors associated with foot/ankle pain severity, as measured via MOXFQ-index
| Unstandardised Bcoefficients (95% CI) | Standardised | |||
|---|---|---|---|---|
| Block 1: Demographic variables | Age | 0.17 (−0.09 to 0.43) | 0.11 | 0.201 |
| Sex (female) | 1.25 (−6.10 to 8.60) | 0.03 | 0.738 | |
| Body mass index | 1.18 (0.59 to 1.77) | 0.33 | < 0.001 | |
| Block 2: Addition of psychological variables | Age | 0.26 (0.04 to 0.48) | 0.16 | 0.021 |
| Sex (female) | 0.59 (−5.67 to 6.84) | 0.13 | 0.853 | |
| Body mass index | 0.87 (0.37 to 1.37) | 0.24 | < 0.001 | |
| Pain catastrophisation (present) | 20.07 (12.87 to 27.27) | 0.41 | < 0.001 | |
| Depressive symptoms (present) | 8.97 (0.81 to 17.13) | 0.21 | 0.031 | |
| CSS (present) | 1.33 (−6.68 to 9.34) | 0.03 | 0.743 |
Dichotomously coded variables include sex (males = 0, females = 1), pain catastrophising (1 = catastrophisation, 0 = non-catastrophisation), depressive symptoms (1 = present, 0 = absent), and CSS (1 = present, 0 = absent)
Abbreviations: CI confidence interval, CSS central sensitisation syndrome, MOXFQ Manchester-Oxford Foot and Ankle Questionnaire